PSA Pharma: What is the Addressable Market for GNI’s (2160 JT) Hydronidone?
On 22 May, GNI Group (2160 JT) subsidiary Gyre Therapeutics (GYRE US) reported that hydronidone had met its primary target in its Chinese Phase III trials and Gyre is now preparing an NDA in China, plus an IND in the US. In this update, Pelham Smithers reviews the potential of GNI.GNI Group is a vertically integrated multinational bio-pharma company, comprised of drug research, clinical development, manufacturing, sales and marketing. Co.'s group base of operations is in China, enabling it to leverage that country's comparative cost advantage in clinical trials to develop Class 1 "First to Market" drug products for the Chinese domestic market. Co. researches and develops therapeutic agents, including Etuary® for radiation pneumonia (RP) and idiopathic pulmonary fibrosis (IPF), F351 for liver fibrosis (cirrhosis), Tamibarotene for acute promyelocytic leukemia (APL), and F573 for acute hepatic insufficiency and acute chronic liver failure (ACLF).
Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods.
PSA produces both company and sector reports. The focus of PSA’s research is to identify winners and losers as new technologies impact the top and bottom lines of corporations. Critical to our research is the clear explanation of how these new technologies work and how they impact companies and industries.
The founding partners have worked closely together for twenty years and the team has more than doubled in size since 2012.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.